Moreover, KRAS mutation is associated with decreased CD8 T infiltration and HLA expression in CRC, and, consequently, KRAS mutant tumor cells have a lower chance of being recognized by T cells34. The gene discussed is CD8A; the disease is colorectal carcinoma.